Epilepsy Research
Volume 27, Issue 3 , Pages 195-204 , June 1997

A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy1

  • Pierre Alfred Bill

      Affiliations

    • Department of Neurology, Wentworth Hospital, Durban, South Africa
    • ,
  • Ulf Vigonius

      Affiliations

    • Novartis Sverige AB, Västra Frölunda, P.O. Box 1150, S-18311 Taeby, Sweden
    • Corresponding Author InformationCorresponding author.
    • ,
  • Harald Pohlmann

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland
    • ,
  • Carlos Alberto M Guerreiro

      Affiliations

    • Department of Neurology, University of Campinas, UNICAMP, Campinas, Brazil
    • ,
  • Silvia Kochen

      Affiliations

    • Centre of Epilepsy, Division of Neurology, UBA, Hospital Ramos Mejia, Buenos Aires, Argentina
    • ,
  • David Saffer

      Affiliations

    • Department of Neurology, Baragwanath Hospital, Johannesburg, South Africa
    • ,
  • Alan Moore

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland

Received 26 March 1997 ,Revised 11 April 1997 ,Accepted 13 April 1997.

References 

  1. Faigle JW, Menge GP. Metabolic characteristics of oxcarbazepine (Trileptal) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol. 1990;3(1):21–30
  2. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs. 1992;43:873–888
  3. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanism of action. Epilepsia. 1994;35(5):S47–S50
  4. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989;3(1):70–76
  5. Reinikainin KJ, Keraenen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res. 1987;1(5):284–289
  6. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87(3):224–227
  7. for the OT/F10 Study Group Vigonius U, Moore A, Kraemer G, Canger R, Deisenhammer E, Schiwy W. Oxcarbazepine: Results of a clinical trial designed to assess the feasibility of a twice-daily administration. Epilepsia Abstr. 1995;36(3):S119
  8. Dam M. Drug therapy for different types of seizures. In: Sillanpää M, Johannessen SI, Blennow G, Dam M, editors. Paediatric Epilepsy. Wrightson Biomedical, 1990:269–278.
  9. Brodie MJ. Established anticonvulsants and treatment of refractory epilepsy. Lancet. 1990;336:350–354
  10. The Commission on Classification and Terminology of the International League Against Epilepsy, Proposal for revised clinical and electroencephalographic classification of epileptic seizures, Epilepsia 22 (4) (1981) 489–501.
  11. Mattson RH, Cramer JA, Collins JF, et al.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313:145–151
  12. Sander JWAS. Some aspects of prognosis in epilepsies. Epilepsia. 1993;34:1007–1016
  13. Trileptal Summary of Product Characteristics, Ciba-Geigy, Basel, March 24 1993.
  14. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carmazepine and oxcarbazepine therapy. Epilepsia. 1994;35(1):181–188

PII: S0920-1211(97)00024-7

Epilepsy Research
Volume 27, Issue 3 , Pages 195-204 , June 1997

Article Tools

* Image Usage & Resolution